Clinical benefits of PD-1/PD-L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and meta-analysis
ConclusionsPD-1/PD-L1 inhibitors showed favorable outcomes concerning response rates and survival periods in advanced HCC. Updated results from high-quality clinical trials are expected to validate these findings.
Source: Hepatology International - Category: Infectious Diseases Source Type: research
More News: Cancer & Oncology | Carcinoma | Clinical Trials | Databases & Libraries | Hepatocellular Carcinoma | Infectious Diseases | Liver Cancer | Science | Study